Gsk Share Discussion Threads

[racg] 16/5/2015 18:18

Well they obviously can Read the bible.

[montyhedge] 16/5/2015 18:01

Read the Investors Chronicle. Not very flattering. The only thing holding this shareprice up is the dividend yield.
They can't keep paying that rate coming years.

[jadeticl3] 16/5/2015 17:44

I find Monty nauseating. He writes unthinking rubbish and changes his mind without reason. Please don't even credit him with honest mistakes.

[nick54] 15/5/2015 16:19

of course he doesn't

[sicker] 15/5/2015 15:59

Group expects to pay annual ordinary dividend of 80p for each of the next three years (2015-2017)
So you know better Monty ?

[racg] 15/5/2015 15:55

Anything to back up your view of the dividend cut? Seeing as they've just stopped a capital return and committed to a 3 year hold on dividends - your assumption and target seem fairly wild.

[montyhedge] 15/5/2015 15:34

1050p target. Dividend in my view will be cut, p.e 24 so 700p target possible.I'm being generous.

[christh] 15/5/2015 12:40

well falling now...where is going to stop, £14 or will drop to £13.80.
Another one for long term.

[speedsgh] 15/5/2015 12:27

"A chap called Troy sold 13250 ADRS this month."

Thunderbirds are go!

[anhar] 15/5/2015 12:25

According to ADVFN figures the company is trading at a PE ratio of 24.95 yet paying a dividend (Quarterly) of 5.06% p.a. at todays price.

That is surely not sustainable long term without growth so I believe a dividend cut is on the way in the next couple of years.

>Anhar what is your view since you hold for dividend?

I don't have one. All I know is that, in an unusual commitment by a company, GSK is likely to pay 80p per year for the next three years plus a 20p special this year. But I'd remain in GSK even without that knowledge because it hasn't triggered my usual sell rule.

I don't consider the longer term future of my shares because I don't have a clue and I don't have faith in anyone's else's view on that either. When I buy a HY share for my port. I just consider the immediate future for divis, the next year or two at the outside, and a few other factors. Once I'm in I take very little interest in it until its yield approaches the market and if it ever gets there, that's my goodbye point.

If it does cut its divi as you suggest, this doesn't alter my strategy. I will simply look at the yield then, against the market, and either hold or sell in my normal way.

[daveofdevon] 15/5/2015 12:20

I don't see much director buying !!!

Last October Witty sold 70,000 shares then in February he sold a further 24,500

A chap called Troy sold 13250 ADRS this month.

The rest of the shares this month were a free gift under bonus plans.

[christh] 15/5/2015 11:53

In my opinion this will move to around £14.75p-£;15.20p.
It has a very strong portfolio of best seller products which are in high demand
and will show that in the next quarterly review.
I have added today for a long term yield and growth.

What made me BUY?

The directors have bought and follow suit as Slater says!

[el chupacabra] 15/5/2015 10:35

its trading 2 standard deviations below fair value in this current uptrend. Also approaching a support line at teh YTD flat line.

[darias] 15/5/2015 10:27

According to ADVFN figures the company is trading at a PE ratio of 24.95 yet paying a dividend (Quarterly) of 5.06% p.a. at todays price.

That is surely not sustainable long term without growth so I believe a dividend cut is on the way in the next couple of years.

>Anhar what is your view since you hold for dividend?

[darias] 15/5/2015 10:21

I can see this going to November levels but that is an opportunity to top up not sell.

[darias] 15/5/2015 10:20

Of Course

They give their recommendation to their customers before releasing to the market. Bit like insider dealing but legal all the information to support their recommendation is out there.

[dr biotech] 15/5/2015 06:53

Price goes down, then broker lowers target. They follow rather than lead.

[christh] 14/5/2015 17:06

DIRECTORS BEING GIVEN/GRANTED SHARES AT £14.73
-----------------------------------------------------------------
Tue 12 May 2015 13:10
RNS Number : 9406M
GlaxoSmithKline PLC
12 May 2015


GlaxoSmithKline plc
Notification of Transactions of Directors, Persons Discharging Managerial Responsibilities or Connected Persons

I give below details of changes in interests in the Ordinary shares of GlaxoSmithKline plc ('GSK') in respect of the under-mentioned Persons Discharging Managerial Responsibilities ('PDMR') on 11 May 2015:

PDMR
GSK Deferred Annual Bonus Plan
E Walmsley
Exercise of a nil priced option over 12,432 shares and 1,679 shares granted on 9 March 2012, both of which vested on 9 March 2015 under the GSK Deferred Annual Bonus Plan. GSK delivered the net of tax value in shares being 7,478.

P Vallance
Exercise of a nil priced option over 24,907 shares and 3,363 shares granted on 9 March 2012, both of which vested on 9 March 2015 under the GSK Deferred Annual Bonus Plan. GSK delivered the net of tax value in shares being 14,983.

C Thomas
Exercise of a nil priced option over 17,986 shares and 2,429 shares granted on 9 March 2012, both of which vested on 9 March 2015 under the GSK Deferred Annual Bonus Plan. GSK delivered the net of tax value in shares being 10,819.

D Redfern
Exercise of a nil priced option over 14,644 shares and 1,977 shares granted on 9 March 2012, both of which vested on 9 March 2015 under the GSK Deferred Annual Bonus Plan. GSK delivered the net of tax value in shares being 8,809.

The fair market value of an Ordinary Share at the point of exercise on 11 May 2015 was £14.73.

The Company and the above-mentioned PDMR's were advised of this transaction on 12 May 2015.

This notification relates to a transaction notified in accordance with paragraph 3.1.4R(1)(a) of the Disclosure and Transparency Rules.

V A Whyte

Company Secretary
12 May 2015

[christh] 14/5/2015 17:02

MJ19 14 May'15 - 16:43 - 10736 of 10736

GlaxoSmithKline: UBS downgrades to neutral and pares target price to 1,500p from 1,700p.

[dr biotech] 14/5/2015 15:38

If GSK is going towards a more high volume low margin model then I wouldn't be surprised to see it broken up and sold off. You would essentially have a vaccines/consumer health/ViiV divisions that really offer little benefit as being part of a conglomerate. The consumer healthcare does offer stability vs the high risk drug discovery - but if that is no longer the focus then there is little point in keeping the group together. I doubt there would be a takeover though.

[nik rosa] 14/5/2015 15:33

....but as we saw with AZN before, govt put the block on large-scale t/o's.
Particularly in pharma sector.

[topcar] 14/5/2015 13:17

AZN is more of a T/o target, 50bill mkt cap, compared to 70bln GSK

AZN far better blockbuster pipe line

turned down £55 ....May be, could be taken out now at £60 !!

Would look very cheap in future years, if all come on stream,

U would be looking at £85 +

Trading a £44 today, looks very tempting, dont rule this out in near future !!

[christh] 14/5/2015 13:08

racg 14 May'15 - 12:45 - 10731 of 10731

That's the right attitude.
Quality stock, and the price to buy now, a great opportunity at bottom price.
High yield, a stock held in all investing funds, ftse stock.

[racg] 14/5/2015 12:45

I ve got enough in glaxo now. So over the next 10 years I m sure we will be ok. Whether or not it just remains a yield stock or transmogrifies into a growth stock. I m holding.